Moreover, a single infusion of the AAV-FVIII SQ variant (AAV5-hFVIII-SQ) showed sustained clinically relevant benefits with a decrease in bleeding events, and no need for prophylactic FVIII use in severe hemophilia A patients in a multiyear follow-up study [177]. This evidence concerns the gene F8 and hemophilia A.